主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CGTX
#3362
Cognition Therapeutics, Inc. Common Stock
1.0
9
-5.22%
版块:
基础:
利润货币:
日范围
年范围
日变化
-5.22%
每月变动
-18.66%
6个月变化
-58.87%
年变化
+142.22%
前一天收盘价
1.1
5
Open
1.0
9
Bid
Ask
Low
1.0
9
High
1.0
9
交易量
16
市场
股票
医疗保健
CGTX
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
22.58 M
29.26 M
39 M
61.97 M
—
Valuation ratios
Enterprise value
87.98 M
18.43 M
45.74 M
18.45 M
119.97 M
Price to earnings ratio
-2.02
-2.25
-2.26
-0.82
-4.89
Price to sales ratio
24.56
1 730.8
2 157.65
-142.89
—
Price to cash flow ratio
9.04
2.61
3.64
0.98
4.62
Price to book ratio
0.64
1.2
2.38
1.49
3.1
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
-0.2
-0.42
-0.73
-1.12
-1.08
Return on equity %
-0.23
-0.53
-1.05
-1.81
-2.2
Return on invested capital %
-7 279.36
-4 738.31
-4 705.93
-7 741.22
—
Gross margin %
100
100
100
100
—
Operating margin %
-2 140.57
-155.54 K
-187.87 K
27.67 K
—
EBITDA margin %
—
—
—
—
—
Net margin %
-876.95
-76.42 K
-95.51 K
17.42 K
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
7.5
6.11
3.37
2.65
12.73
Inventory turnover
—
—
—
—
—
Asset turnover
0.02
0
0
-0.01
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.7
-0.78
-0.53
-0.72
-0.54
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
10.54
1.76
1
0.63
1.65
Net current asset value per share
11.36
2.02
1.14
0.74
2.06
Tangible book value per share
9.88
1.7
0.82
0.47
1.32
Working capital per share
9.85
1.69
0.8
0.46
1.3
Book value per share
9.88
1.7
0.82
0.47
1.32
新闻
认知治疗公司与FDA就路易体痴呆症药物举行会议
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug
认知治疗公司的DLB药物在二期临床试验中显示积极结果
Cognition’s DLB drug shows positive results in phase 2 trial
认知治疗公司完成扩展获取计划的患者招募
Cognition Therapeutics completes enrollment in expanded access program
认知治疗公司概述阿尔茨海默病药物的三期试验计划
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug
Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold (NASDAQ:CGTX)
认知治疗公司完成阿尔茨海默病药物试验招募
Cognition Therapeutics completes enrollment in Alzheimer’s drug trial
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?